Malignant neoplasm, pancreas
Disease

Medical Tests (70)
Screening/Initial Testing (6)
Diagnostic Testing (12)
Hepatic Function Panel (Liver Panel)
8
Note:

Some component of this panel might be part of the comprehensive metabolic panel.

Insulin, Random
7
Note:

Rule out cancer of islet cells.

Gamma Glutamyl Transferase (GGT)
6
Note:

Ruel out liver disease.

Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis
5
Note:

EGFR is expressed 30-50% in Pancreatic ductal adenocarcinoma (PDAC). http://www.ncbi.nlm.nih.gov/pubmed/26361407

KRAS Gene Mutation Analysis
5
Note:

Not specific for pancreas cancer, but helpful in therapy treatment.

Disease Management Testing (5)
NTRK Gene Fusion Panel (NTRK1, NTRK2, and NTRK3), Solid Tumors
6
Note:

In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Other Supportive/Alternative Tests (47)
Basic Metabolic Panel (BMP)
7
Note:

Alternative to Comprehensive Metabolic Panel.

IMMray, PanCan-d Test for Early Detection of Pancreatic Cancer
7
Note:

Early detection of pancreatic cancer.

Cytochrome P450 2A6 (CYP2A6) Genotyping
6
Note:

Determine therapeutic strategy for cancer therapeutics such as Tegafur.

Occult Blood, Fecal
6
Note:

Rule out gastrointestinal cancer and bleeding.

Avantect Pancreatic Cancer Test
5
Note:

Early detection of pancreatic cancer.

Comprehensive Pharmacogenetics (PGx) Gene Variation Panel
5
Note:

Please use “Pain Management Pharmacogenetics Gene Variation Panel” if testing ordered for pain management. This panel is comprehensive, and it is general and not specific for pain management.

DNA Cell Cycle Analysis by Flow Cytometry
5
Note:

Used in prognosis of malignancy.

Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
5
Note:

Therapy selection and management.

Ferritin
5
Note:

If iron is low due to anemia.

HelioLiver™ Methylation Assay for Hepatocellular Carcinoma
5
Note:

Rule out hepatocellular carcinoma.

Iron Binding Capacity
5
Note:

If hemoglobin is low due to anemia.

Iron, Serum
5
Note:

If hemoglobin is low due to anemia.

LiquidHALLMARK Multi Cancer Panel
5
Note:

Aid in the diagnosis and management.

MLH1 Hypermethylation (Promoter Methylation) Analysis, Tissue
5
Note:

Supportive in diagnosis and treatment.

Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1) Gene Mutation Analysis (Translocation)
5
Note:

In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Gene Mutation Analysis (Translocation)
5
Note:

In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Neurotrophic Receptor Tyrosine Kinase 3 (NTRK3) Gene Mutation Analysis (Translocation)
5
Note:

In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Solid Organ or Hematolymphoid Neoplasm Gene Mutation Panel, NGS
5
Note:

Alternative to specific genetic markers. Good for therapy selection and monitoring.

Tempus PurIST℠ Pancreatic Cancer Test
5
Note:

Tempus’ PurISTSM test identifies the molecular subtype of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma.

Transferrin and Transferrin Saturation
5
Note:

IF iron is low due to anemia.

Cancer Antigen Profile
4
Note:

Individual cancer test tissue specific is recommended.

ICD10
C25Malignant neoplasm of pancreas
C25.0Malignant neoplasm of head of pancreas
C25.1Malignant neoplasm of body of pancreas
C25.2Malignant neoplasm of tail of pancreas
C25.7Malignant neoplasm of other parts of pancreas
C25.9Malignant neoplasm of pancreas, unspecified
Z51.1Encounter for antineoplastic chemotherapy and immunotherapy
Z79Long term (current) drug therapy
Z79.899Other long term (current) drug therapy
Z85Personal history of malignant neoplasm
Z85.07Personal history of malignant neoplasm of pancreas

Additional ICD10
C25.0Malignant neoplasm of head of pancreas
C25.1Malignant neoplasm of body of pancreas
C25.2Malignant neoplasm of tail of pancreas
C25.3Malignant neoplasm of pancreatic duct
C25.4Malignant neoplasm of endocrine pancreas
C25.7Malignant neoplasm of other parts of pancreas
C25.8Malignant neoplasm of overlapping sites of pancreas
C25.9Malignant neoplasm of pancreas, unspecified
D13.6Benign neoplasm of pancreas
D61.810Antineoplastic chemotherapy induced pancytopenia
D64.81Anemia due to antineoplastic chemotherapy
D70.1Agranulocytosis secondary to cancer chemotherapy
P04.11Newborn affected by maternal antineoplastic chemotherapy
T80.810Extravasation of vesicant antineoplastic chemotherapy
T80.810AExtravasation of vesicant antineoplastic chemotherapy, initial encounter
T80.810DExtravasation of vesicant antineoplastic chemotherapy, subsequent encounter
T80.810SExtravasation of vesicant antineoplastic chemotherapy, sequela
Z51.1Encounter for antineoplastic chemotherapy and immunotherapy
Z51.11Encounter for antineoplastic chemotherapy
Z79.5Long term (current) use of steroids
Z79.8Other long term (current) drug therapy
Z79.89Other long term (current) drug therapy
Z79.891Long term (current) use of opiate analgesic
Z79.899Other long term (current) drug therapy
Z85.0Personal history of malignant neoplasm of digestive organs
Z85.00Personal history of malignant neoplasm of unspecified digestive organ
Z85.05Personal history of malignant neoplasm of liver
Z85.07Personal history of malignant neoplasm of pancreas
Z92.21Personal history of antineoplastic chemotherapy

SNOMED
372003004Primary malignant neoplasm of pancreas